GLANZMANN THROMBASTHENIA NATURAL HISTORY STUDY+
Recruiting
- Conditions
- Glanzmann thrombastheniaGlanzmann's disease10035534
- Registration Number
- NL-OMON56766
- Lead Sponsor
- niversitair Medisch Centrum Utrecht
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 30
Inclusion Criteria
o Adult patients (>=16 years);
o Biochemically or genetically diagnosed Glanzmann thrombasthenia.
o Willing and able to give written informed consent
Exclusion Criteria
- Patients with acquired thrombasthenic states caused by auto-immune disorders
or drugs.
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>To determine the genetic phenotype in patients with Glanzmann thrombasthenia. </p><br>
- Secondary Outcome Measures
Name Time Method <p>To estimate the prevalence of Human Leukocyte antigens (HLA) and Human Platelet<br /><br>Antigens (HPA) antibodies in patients with Glanzmann thrombasthenia. These<br /><br>antibodies may develop as a consequence of treatment with the current golden<br /><br>standard: platelet transfusion or transfusion with other blood products<br /><br>including red blood cells and plasma.<br /><br><br /><br>Together with the data from the Glanzmann-NHS registry, results from the<br /><br>Glanzmann-NHS+ study will allow to investigate whether there are correlations<br /><br>between genotype and clinical phenotype (bleeding score).</p><br>